649-SPYTAC: Peptide Platform for Amyloid-β Degradation
The paper describes the development of SPYTACs, a novel synthetic peptide platform designed to treat Alzheimer’s disease through targeted protein degradation. By utilizing the LRP1 receptor, these bifunctional peptides facilitate the transport of toxic amyloid-β proteins to lysosomes for clearance in both the brain and the liver. Research conducted on 5×FAD mice demonstrates that this technology effectively crosses the blood-brain barrier to reduce plaque buildup and improve cognitive performance. Notably, the study highlights that SPYTACs achieve these therapeutic results with significantly…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.